|Bid||33.04 x 0|
|Ask||33.14 x 0|
|Day's Range||32.77 - 33.53|
|52 Week Range||32.77 - 33.53|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 22, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, British Columbia & SEATTLE, January 19, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
VANCOUVER, British Columbia & SEATTLE, January 15, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the "NYSE Rule"), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks’ new Chair, President and Chief Executive Officer.
The big shareholder groups in Zymeworks Inc. ( NYSE:ZYME ) have power over the company. Generally speaking, as a...